CD8A and acute myeloid leukemia: Recent data suggest the potential of combining VEN with immunotherapeutic strategies, as a study employing a murine model of AML treated with a combination of VEN with anti-PD-1 therapy led to higher CD8+ T cell proliferation and enhanced blast clearance compared to the combination of AZA+VEN [187].